Brief: Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA
09/04/2025 11:38
April 9 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: TQB3019 (BTK PROTAC) APPROVED FOR CLINICAL TRIAL BY NMPA Further company coverage: 1177.HK ((Reuter.Briefs@thomsonreuters.com))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit